• Cyclerion held its annual shareholder meeting on Aug. 26, 2026, with investors voting on merger-related proposals.
• Share issuance tied to the merger won shareholder backing, clearing a change-of-control step linked to the transaction.
• Charter amendment to raise authorized common shares to 700 million from 400 million was adopted.
• Reverse stock split was authorized; the board later set a 1-for-7 ratio, pending effectiveness upon filing.
• Redomestication to the Cayman Islands failed; the combined company is expected to trade as Korsana Biosciences under KRSA on Sept. 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclerion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-369426), on August 27, 2026, and is solely responsible for the information contained therein.